Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 12, Issue 13, Pages 2069-2074Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2011.590133
Keywords
castrate resistant; chemotherapy; outcomes; prostate cancer; review
Categories
Ask authors/readers for more resources
Introduction: Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available